Long Survival with Islet Cell Carcinoma of the Pancreas

Kernen, Jules A.; Scofield, G. F.; Koucky, Charles J.; Benitez, Roberto E.; Ackerman, Lauren V.

doi:10.1093/ajcp/39.2.137

Cited by 23 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of these effects, with the exception of the changes in serum immunoreactive insulin, long have been known to be features of epinephrine release. 10 " 21 Recently we have demonstrated that epinephrine inhibits insulin secretion in normal subjects, 22 and Coore and Randle 23 have shown that epinephrine inhibits glucose-induced insulin release from rabbit pancreas in vitro. The present report shows that epinephrine infusion has similar effects in diabetic subjects and a patient with an islet cell carcinoma.…”

Section: Epinephrine Infusionsmentioning

confidence: 99%

Clinical Use of Diazoxide and Mechanism for Its Hyperglycemic Effects

1966

View full text Add to dashboard Cite

The mechanism of diazoxide hyperglycemia in man has been studied by measurement of serum glucose, immunoreactive insulin, and plasma free fatty acids. In a patient with islet cell carcinoma, in normal subjects, and in diabetic patients, diazoxide hyperglycemia was accompanied by a decrease in serum immunoreactive insulin, an increase in plasma free fatty acids, tachycardia, and a widened pulse pressure. The similarity of these effects to those produced by epinephrine has suggested that at least some of the effects of diazoxide may be mediated by endogenous sympathetic stimulation. Diazoxide has been used successfully to control hypoglycemia in a patient with islet cell carcinoma for twenty months. DIABETES 15: 143-48, March, 1966.

show abstract

Section: Epinephrine Infusionsmentioning

confidence: 99%

Clinical Use of Diazoxide and Mechanism for Its Hyperglycemic Effects

1966

View full text Add to dashboard Cite

show abstract

“…With islet cell tumours, survival is longer than with exocrine tumours of the pancreas, but exact figures are hard to assess because of difficulties in histological classification. Kernen et al [13] reviewed the course of patients with islet cell carcinoma, malignant by virtue of metastases or aggressive infiltrative growth into the Diabstologia surrounding tissue. Sixteen patients survived for at least three years after the pathological diagnosis was made, and one patient was alive 13 years after biopsy of hepatic metastases.…”

Section: Discussionmentioning

confidence: 99%

Treatment of malignant insulinoma with streptozotocin

et al. 1971

View full text Add to dashboard Cite

Two patients with malignant insulinoma and hepatic metastases were treated with streptozotoein, administered directly into the celiac artery. Decreases in tumor size were documented radiographically. One patient was in a terminal state when first treated, but the other patient was in moderately good general health and responded well. Some side-effects, including renal tubular damage, were observed but were relatively minor. Streptozotocin therapy offers some benefit in patients ~vith malignant insulinoma. Traitement de l'insulinome malin par la streptozotocine Rdsumd. Deux patients attcints d'insulinome avec m6tastases h@atiques ont 6t6 trait@s par injection de streptozotoeinc darts l'artgre coeliaque. Une diminution des dimensions de la tumcur a 6t6 mise en 6vidence radiologiquement. L' un des patients trait dans un 6tat ferminal au moment o~ le traitement a 6t6 institu6; l'autre patient dent l'@tat g@n6ral ~tait relativement ben a bien r6pondu ~ la th6rapeutique. Certains effets eollatdraux dent des signes d'attcinte r6nale tubulaire, ont 6t6 not6s mais sent relativement peu importants. La streptozotocine offrc done un certain inter6t dans le traitement de l'insulinomc malin. Die Behandlung des maligne~ Insulinoms mit Streptozotocin Zusammenfassung. Zwei Patienten mit metastasiercndem Insulinom wurde Streptozotozin in die Arteria cocliaca verabrcieht. Daraufhin liel3 sich radiographisch ein Riiekgang der TumorgrSl3e nachweiscn. Bei Therapiebeginn bcfand sich ein Patient in m/~l]igem, dcr andere in schr schlechtem Allgcmcinzustand. Einige Nebenwirkungcn, insbcsondere Sch/idigung der Nierentubuli, traten auf, waren abet yon geringem Ausmal3. Streptozotozin ist geeignet, Patienten, die an einem malignen Insulinom leiden, Gin@rung zu verschaffen.

show abstract

The role of morphometry in predicting prognosis in pancreatic islet cell tumors

Kenny¹,

Sloan²,

Hamilton

et al. 1989

Cancer

View full text Add to dashboard Cite

Morphometry of 31 pancreatic islet cell tumors was examined to determine the value of this technique in assessing tumor behavior. Patients were followed for a mean period of 5.1 years (range, 1 month-14 years) after diagnosis. Initially 17 localized and nine metastatic tumors were studied. Discriminant analysis was carried out on these cases and identified nuclear/cytoplasmic ratio and number of nuclei/mm2 as the significant discriminatory features. These were combined to derive a classification rule which was capable of correctly identifying localized and metastatic tumors in 92% of cases. The classification rule was applied subsequently to an additional five test cases, all of which were classified successfully. The failure of increased nuclear size and pleomorphism to correlate with malignancy in these tumors was confirmed. Tumors which metastasized had significantly greater gross diameters than localized lesions, but overlap existed. Mitotic counts were not a helpful discriminatory feature. Morphometry may be useful in improving histologic assessment of pancreatic islet cell tumor behavior.

show abstract

Long Survival with Islet Cell Carcinoma of the Pancreas

Cited by 23 publications

References 0 publications

Clinical Use of Diazoxide and Mechanism for Its Hyperglycemic Effects

Clinical Use of Diazoxide and Mechanism for Its Hyperglycemic Effects

Treatment of malignant insulinoma with streptozotocin

The role of morphometry in predicting prognosis in pancreatic islet cell tumors

Contact Info

Product

Resources

About